Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer

[1]  Xiangwu Zheng,et al.  Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT , 2019, Annals of Nuclear Medicine.

[2]  L. Mansi,et al.  Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Henrik Møller,et al.  Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  K. Franks,et al.  Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence? , 2018, Current Surgery Reports.

[5]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[6]  B. Oliveiros,et al.  Metabolic tumor burden quantified on [18F]FDG PET/CT improves TNM staging of lung cancer patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Y. Pu,et al.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Jinming Yu,et al.  Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis , 2016, PloS one.

[9]  M. Salvatore,et al.  18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study , 2015, Clinical nuclear medicine.

[10]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[11]  Kyoungjune Pak,et al.  Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Bernd J. Pichler,et al.  Image-derived biomarkers and multimodal imaging strategies for lung cancer management , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  A. Brunetti,et al.  Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography , 2014, Clinical Cancer Research.

[14]  R. Subramaniam,et al.  PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. , 2013, AJR. American journal of roentgenology.

[15]  Michele Larobina,et al.  Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma , 2012, The Journal of Nuclear Medicine.

[16]  Nan-Tsing Chiu,et al.  Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. , 2012, Radiology.

[17]  Kristin D. Brockway,et al.  What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. , 2012, International journal of radiation oncology, biology, physics.

[18]  Martin Hutchings,et al.  PET/CT for Therapy Response Assessment in Lymphoma , 2009, Journal of Nuclear Medicine.

[19]  I. Matsunari,et al.  Value of whole-body FDG PET in management of lung cancer , 2003, Annals of nuclear medicine.

[20]  N. Sunaga,et al.  Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Frank C. Detterbeck,et al.  The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.

[22]  B. Loo,et al.  Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235 , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  H. Satoh,et al.  Specific organ metastases and survival in metastatic non-small-cell lung cancer. , 2015, Molecular and clinical oncology.

[24]  Su Jin Lee,et al.  The prognostic value of total lesion glycolysis via 18F-fluorodeoxyglucose PET–CT in surgically treated esophageal squamous cell carcinoma , 2015, Annals of Nuclear Medicine.

[25]  B. C. Penney,et al.  Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. , 2013, Academic radiology.

[26]  Peter Smeets,et al.  Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  B. C. Penney,et al.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  M. Meziane,et al.  Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. , 2011, Chest.